Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals ( ($SUPN) ) has shared an update. On May 17, 2026, Supernus Pharmaceuticals notified its rights agent that Milestone 1 und...

Supernus Reaches Milestone, Triggers Contingent Value Rights Payment

Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals today and set a price target of $55.00. Samimy covers t...

Stifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Supernus Pharmaceuticals, with a price target of $66.00. A...

Market Cap	$2.81B	P/E Ratio	28.70
52W High	$59.68	52W Low	$30.83
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-100.0%	52W Position	60.2%
Overall Score	43	Value Score	40
Quality Score	60	Technical Score	30

EPS Current Est	$1.68	EPS Next Est	$3.61
EPS Growth Est	+114.9%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SUPN	$48.21	-2.37%	526.84K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SUPN	$48.21	-2.4%	526.84K
3
4
5
6

SUPN

SUPN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Supernus Pharmaceuticals Inc. Data in Excel

Get Supernus Pharmaceuticals Inc. Data in Excel